RxDoctor Payments Data

Gary Shienbaum, MD

Ophthalmology · Hollywood, FLNPI 1770781502

Payments from drug & device makers

$14,217in general payments, 2019–2025

Across 84 payments — averaging $169.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$12K
  • Regeneron Healthcare Solutions, Inc.$750
  • AbbVie$447
  • Genentech USA, Inc.$436
  • Apellis Pharmaceuticals, Inc.$202
  • Alimera Sciences, Inc.$167
  • plus $424 from 7 others

What the payments were for

  • Food & beverage$2,427100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,217 in reported general payments places this provider in the 80th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$1,010,388
Medicare patients
413
Services billed
21,482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EyleaAflibercept82$266,118
VabysmoFaricimab-Svoa59$153,195
Eylea HdAflibercept16$61,473
SyfovrePegcetacoplan/Pf14$61,234
IlevroNepafenac43$16,403
Prednisolone Acetate125$6,550
CombiganBrimonidine Tartrate/Timolol13$5,664
Difluprednate26$3,387
Ketorolac Tromethamine119$3,282
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat115$1,951
Bromfenac Sodium12$1,755
Brimonidine Tartrate42$1,428
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha52$546
Latanoprost53$484
Dorzolamide Hcl12$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Regeneron Healthcare Solutions, Inc.Eylea, Eylea Hd$750$327,59198 claims
Genentech USA, Inc.Vabysmo$436$153,19559 claims
Apellis Pharmaceuticals, Inc.Syfovre$202$61,23414 claims
NovartisIlevro$11,790$16,40343 claims
AbbVieCombigan$447$5,66413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →